NCT00312130

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

A Single-blind, Single-treatment Study to Evaluate the Effects of Vildagliptin on Response to an Intravenous Glucose Load in Pre-diabetic Subjects With Impaired Fasting Glucose

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (planned)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.

Conditions

• Pre-diabetes

Interventions

Type	Name	Description
DRUG	Vildagliptin

Timeline

• Start date: 2005-04-01
• Primary completion: 2006-11-01
• Completion: 2006-11-01
• First posted: 2006-04-07
• Last updated: 2016-11-18

Locations

1 site across 1 country: United States